Not surprisingly, small molecule inhibitors of the p53-Mdm2 interaction are being actively investigated and some of them have reached different stages of clinical trials as anti-cancer therapeutics for different types of cancer (Davidovich et al., 2015; Lezina et al., 2015; Konopleva et al., 2020). This evidence concerns the gene MDM2 and cancer.